NO940660L - HLA - begrensete Hepatit B virus CTL-epitoper - Google Patents

HLA - begrensete Hepatit B virus CTL-epitoper

Info

Publication number
NO940660L
NO940660L NO940660A NO940660A NO940660L NO 940660 L NO940660 L NO 940660L NO 940660 A NO940660 A NO 940660A NO 940660 A NO940660 A NO 940660A NO 940660 L NO940660 L NO 940660L
Authority
NO
Norway
Prior art keywords
hbv
peptides
hla
restricted
hepatitis
Prior art date
Application number
NO940660A
Other languages
English (en)
Norwegian (no)
Other versions
NO940660D0 (no
Inventor
Maria A Vitiello
Robert W Chesnut
Original Assignee
Cytel Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytel Corp filed Critical Cytel Corp
Publication of NO940660D0 publication Critical patent/NO940660D0/no
Publication of NO940660L publication Critical patent/NO940660L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO940660A 1991-08-26 1994-02-25 HLA - begrensete Hepatit B virus CTL-epitoper NO940660L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74956891A 1991-08-26 1991-08-26
US82768292A 1992-01-29 1992-01-29
US87449192A 1992-04-27 1992-04-27
PCT/US1992/007218 WO1993003764A1 (en) 1991-08-26 1992-08-26 Hla-restricted hepatitis b virus ctl epitopes

Publications (2)

Publication Number Publication Date
NO940660D0 NO940660D0 (no) 1994-02-25
NO940660L true NO940660L (no) 1994-04-22

Family

ID=27419385

Family Applications (1)

Application Number Title Priority Date Filing Date
NO940660A NO940660L (no) 1991-08-26 1994-02-25 HLA - begrensete Hepatit B virus CTL-epitoper

Country Status (16)

Country Link
EP (2) EP1018344A3 (de)
JP (2) JP3738395B2 (de)
AU (1) AU687725B2 (de)
BG (1) BG98523A (de)
CA (1) CA2115839C (de)
CZ (1) CZ42794A3 (de)
DE (1) DE69231621T2 (de)
ES (1) ES2155060T3 (de)
FI (1) FI940918A (de)
GR (1) GR3035575T3 (de)
HU (1) HUT68510A (de)
IL (1) IL102964A0 (de)
NO (1) NO940660L (de)
NZ (2) NZ270605A (de)
OA (1) OA09888A (de)
WO (1) WO1993003764A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607727B1 (en) 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US6322789B1 (en) 1991-08-26 2001-11-27 Epimmune, Inc. HLA-restricted hepatitis B virus CTL epitopes
US5780036A (en) * 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
US6689363B1 (en) 1992-01-29 2004-02-10 Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
AU4998993A (en) * 1992-08-07 1994-03-03 Epimmune, Inc. Hla binding peptides and their uses
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US6235288B1 (en) 1992-08-26 2001-05-22 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
US9266930B1 (en) 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
ES2180576T3 (es) * 1993-04-27 2003-02-16 United Biomedical Inc Construcciones peptidicas de lhrh inmunogenicas y estimuladores de inmunidad universales sinteticos para vacunas.
US6413935B1 (en) 1993-09-14 2002-07-02 Epimmune Inc. Induction of immune response against desired determinants
JP3926839B2 (ja) * 1993-09-14 2007-06-06 エピミューン，インコーポレイティド 万能ｄｒ−結合性ペプチドを用いる免疫応答の改変
GB9325772D0 (en) * 1993-12-16 1994-02-16 Smithkline Beecham Biolog Novel compounds
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
EP0948533A1 (de) * 1996-12-30 1999-10-13 Innogenetics N.V. Annexin v bindende polypeptidfragmente des hbsag und ihre verwendung
NZ500287A (en) * 1997-04-11 2002-10-25 Sangstat Medical Corp Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
US7105164B1 (en) 1998-04-07 2006-09-12 Sanofi Pasteur Limited HIV-specific cytotoxic T-cell responses
US20010019714A1 (en) * 1998-04-07 2001-09-06 Charles D. Y. Sia Hiv-specific cytotoxic t-cell responses
CU22871A1 (es) 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
ATE445643T1 (de) 1999-11-18 2009-10-15 Pharmexa Inc Heteroklitische analoga von klasse-i epitopen
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
CA2563508A1 (en) * 2004-04-21 2005-11-17 The University Of Chicago Myosin light chain kinase inhibitors and methods of use
JP2010500407A (ja) * 2006-08-14 2010-01-07 サイモン・エル・エル・シー Ｈｉｖ−１の複数の株及びサブタイプを治療及び予防するための組成物及び方法
EP2687541A1 (de) 2006-10-17 2014-01-22 Oncotherapy Science, Inc. Peptidvakzinen für MPHOSPH1- oder DEPDC1-Polypeptide exprimierenden Krebs
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
JP5971945B2 (ja) 2008-04-17 2016-08-17 ピーディーエス バイオテクノロジー コーポレイションＰｄｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ カチオン性脂質の鏡像異性体による免疫応答の刺激
WO2010086294A2 (en) 2009-01-28 2010-08-05 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
US10076570B2 (en) 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection
US9393299B2 (en) 2009-08-07 2016-07-19 Transgene S.A. Composition for treating HBV infection
TWI623618B (zh) 2011-07-12 2018-05-11 傳斯堅公司 Ｈｂｖ聚合酶突變體
US9458447B2 (en) 2011-08-12 2016-10-04 Oncotherapy Science, Inc. MPHOSPH1 peptides and vaccines including the same
US10258676B2 (en) * 2011-09-06 2019-04-16 Agency For Science, Technology And Research Polypeptide vaccine
EP2897639A4 (de) 2012-09-21 2016-05-04 Frank Bedu-Addo Verbesserte impfstoffzusammensetzungen und verfahren zur verwendung
CN103961697A (zh) * 2013-02-05 2014-08-06 日东电工株式会社 粘膜给予用疫苗组合物
KR20140100417A (ko) * 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 경피 투여용 백신 조성물
AU2016306527B2 (en) 2015-08-12 2022-03-17 Oncotherapy Science, Inc. DEPDC1-derived peptide and vaccine containing same
JP6876682B2 (ja) * 2015-09-08 2021-05-26 ウニヴェルズィテート チューリッヒ ネコアレルギーに対する組成物
EP3360885A4 (de) 2015-10-08 2019-04-24 Oncotherapy Science, Inc. Von mphosph1 abgeleitetes peptid und impfstoff damit
CA3005251A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935235A (en) * 1979-05-24 1990-06-19 The Regents Of The University Of California Non-passageable viruses
US5017558A (en) * 1980-01-14 1991-05-21 The Regents Of The University Of California Synthetic vaccine peptide epitomes of hepatitis B surface antigen
JPS60161999A (ja) * 1984-02-02 1985-08-23 Chemo Sero Therapeut Res Inst ペプチド
US4818527A (en) * 1986-12-09 1989-04-04 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US4882145A (en) * 1986-12-09 1989-11-21 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
JPH03504975A (ja) * 1988-06-14 1991-10-31 セル―エスシーアイ　コーポレイション 異種官能性細胞免疫剤、それを含有するワクチン及びその使用方法
IT1238343B (it) * 1989-10-16 1993-07-13 Cesalpino Andrea Fond Procedimento per la preparazione di vaccini capaci di generare non solo la risposta immune dei linfociti t helper,ma anche un'efficace risposta di linfociti t citotossici,e vaccini con queste caratteristiche
EP0510054A1 (de) * 1990-01-05 1992-10-28 United Biomedical, Inc. Hiv-1-core-proteinfragmente

Also Published As

Publication number Publication date
JPH06510051A (ja) 1994-11-10
NZ270605A (en) 1997-07-27
CA2115839C (en) 2010-06-01
IL102964A0 (en) 1993-01-31
NZ244103A (en) 1997-07-27
BG98523A (en) 1995-05-31
EP1018344A2 (de) 2000-07-12
ES2155060T3 (es) 2001-05-01
JP3586278B2 (ja) 2004-11-10
DE69231621T2 (de) 2001-05-31
EP0534615A2 (de) 1993-03-31
AU2548792A (en) 1993-03-16
AU687725B2 (en) 1998-03-05
JP2004075693A (ja) 2004-03-11
NO940660D0 (no) 1994-02-25
FI940918A0 (fi) 1994-02-25
EP0534615B1 (de) 2001-01-03
EP1018344A3 (de) 2000-09-20
CA2115839A1 (en) 1993-03-04
HUT68510A (en) 1995-06-28
HU9400581D0 (en) 1994-05-30
JP3738395B2 (ja) 2006-01-25
FI940918A (fi) 1994-04-08
EP0534615A3 (en) 1994-05-25
OA09888A (en) 1994-09-15
CZ42794A3 (en) 1994-11-16
WO1993003764A1 (en) 1993-03-04
GR3035575T3 (en) 2001-06-29
DE69231621D1 (de) 2001-02-08

Similar Documents

Publication Publication Date Title
NO940660L (no) HLA - begrensete Hepatit B virus CTL-epitoper
NO940661L (no) Peptider for indusering av cytotoksisk T-lymfocytreaksjoner mot hepatit B virus
DK0726758T3 (da) Peptider til inducering af cytotoksiske T-lymfocytreaktioner over for hepaptitis B virus
DE60039715D1 (de) Hcv-impfstoff zusammensetzungen
WO2006086188A3 (en) Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
DE69726734D1 (de) Menschliche monoklonale antikörper gegen das hepatitis b oberflächenantigen
DE69433007D1 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis b virus
Iwarson et al. Hepatitis B immune globulin in prevention of hepatitis B among hospital staff members
PT625204E (pt) Terapeutica da hepatite
Hendrickx et al. Advances in hepatitis immunization (A, B, E): public health policy and novel vaccine delivery
DK0563254T3 (da) Anvendelse af IL-4 til forstærkning af immunrespons på immunogener i vacciner
RU93053037A (ru) Вакцина против заболевания сумки птиц и способы лечения
NO971529D0 (no) Rekombinante proteiner av en Pakistani stamme av hepatitt E og deres anvendelse i diagnostiske metoder og vaksiner
DE3854857D1 (de) Verhütung und behandlung einer retrovirenkrankheit
El-Awady et al. Conserved peptides within the E2 region of Hepatitis C virus induce humoral and cellular responses in goats
Charney et al. Immunization studies with mammary tumor virus
DE60229126D1 (de) Pre-s-protein von hepatitis-b-virus (hbv) als adjuvans und komponente eines hbv-impfstoffs
Ito et al. Antitumor efficacy of vaccinia virus-modified tumor cell vaccine
FI930519A (fi) Peptider foer blokering av infektioner orsakade av hiv-virus samt foerfarande foer deras anvaendnig
RU2006117308A (ru) Фармацевтические композиции для терапевтического применения
Miller Reader'Forum
JPS55312A (en) Hbs antibody and its preparation
Shouval Adoptive immune transfer as a therapeutic approach for persistent hepatitis B virus infection
RU94032103A (ru) Пептиды, фармацевтическая композиция, вакцина, конъюгат, способы лечения и идентификации
CA2156416A1 (en) Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus